On November 14, 2023, Mark Heinen notified Better Therapeutics, Inc. of his resignation as the chief financial officer of the Company, effective November 27, 2023. Frank Karbe, the Company's chief executive officer ("CEO"), will assume the duties of principal financial officer and Leslie Miller, the Company's controller, will assume the duties of principal accounting officer. Mr. Heinens resignation supports a series of expense reduction measures, including voluntary salary reductions by the CEO and other executives, to extend the cash runway sufficiently to demonstrate commercial traction for AspyreRx, and did not result from any disagreement with the Company or any person affiliated with the Company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 USD | +10.00% | -12.00% | -94.36% |
Mar. 21 | Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc | CI |
Mar. 20 | Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-94.36% | 545K | |
+59.34% | 62.59B | |
-2.64% | 41.18B | |
+44.25% | 40.29B | |
-8.29% | 27.9B | |
+12.68% | 26.21B | |
-21.73% | 19.09B | |
+5.95% | 13.08B | |
+24.29% | 12.26B | |
+27.24% | 12.05B |
- Stock Market
- Equities
- BTTX Stock
- News Better Therapeutics, Inc.
- Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023